Urol. praxi. 2019;20(3):119-121 | DOI: 10.36290/uro.2019.060
Multidrug-resistant bacterial infections and their treatment options
- Ústav lékařské mikrobiologie 2. LF UK a FN Motol, Praha
In the setting of increasing resistance in the causative agents of bacterial infections, the choice of antibiotics requires a highly responsible approach. The reasons for this are both achieving a reliable effect and preventing further spread of resistance. Current reviews of resistance are an essential basis for empirical administration, optimally followed by identification and susceptibility testing of a particular pathogen for targeted therapy. The selection of appropriate drugs for treating community-acquired infections (urinary infections) should respect national guidelines, and the treatment of hospital-acquired infections should be adapted to local epidemiological conditions. Several drugs have recently shown promise in treating infections caused by multiresistant microorganisms (ceftolozane/tazobactam, ceftazidime/avibactam, pivmecillinam).
Keywords: urinary infection, multiresistance, resistance reviews, guidelines, antibiotics of choice
Published: July 1, 2019 Show citation
References
- Bush K. Proliferation and significance of clinically relevant ?-lactamases. Ann N Y Acad Sci. 2013; 1277: 84-90.
Go to original source... 
Go to PubMed... - Papagiannitsis CC, Di Pilato V, Gian et al. Characterization of KPC-encodingplasmids from two endemic settings, Greece and Italy. J Antimicrob Chemother. 2016; 71(10): 2824-2830. Go to original source... Go to PubMed...
- Meletis G, Skoura L. Polymyxin Resistance Mechanisms: From IntrinsicResistance to Mcr Genes. Recent Pat Antiinfect Drug Discov. 2018; 13(3): 198-206. Go to original source... Go to PubMed...
- Wang R, van Dorp L, Shaw LP, et al. The global distribution and spread of the mobilized colistin resistance gene mcr-1. Nat Commun. 2018; 21: 1179. Go to original source...
- Falgenhauer L, Ghosh H, Doijad S, et al. Genome Analysis of the Carbapenem-and Colistin-Resistant Escherichia coli Isolate NRZ14408 Reveals Horizontal GeneTransfer Pathways towards Panresistance and Enhanced Virulence. Antimicrob Agents Chemother. 2017; 61: 02359-16. Go to original source...
- Kandil H, Cramp E, Vaghela T. Trends in Antibiotic Resistance in Urologic Practice. Eur Urol Focus. 2016; 2(4): 363-373. Go to original source...
- Nyč O. Novinky a trendy v antibiotické léčbě. Interní Med. 2017; 19(3): 142-144. Go to original source...
- Karanika S, Karantanos T, Arvanitis M, et al. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis. 2016; 63(3): 310-318. Go to original source... Go to PubMed...
- Nyč O, Urbášková P, Marešová V a kol. Konsensus používání antibiotik III. Chinolony. Prakt Lék. 2006; 86(10): 570-574.
- https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc
- Statní Zdravotní Ústav: Močová studie ATB rezistence, výsledky studie za rok 2016. Dostupné z www: http://www.szu.cz/mocova-studie-atb-rezistence
- Bartoníčková K, et al. Doporučený postup pro antibiotickou léčbu komunitních infekcí ledvin a močových cest v primární péči. Dostupné z www: https://www.infekce.cz/dokument1.htm
- Fajfr M, Louda M, Paterová P a kol. Fosfomycin trometamol - staronové antibiotikum v urologické praxi. Urol. praxi, 2015; 16(4): 148-150.
- Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug resistant bacteria. J Antimicrob Chemother 2014; 69: 303-308. Go to original source... Go to PubMed...
- Bonkat R, Pickard R, Bartoletti T, et al. Urological Infections. European Association of Urology 2018. Dostupné z www: http://uroweb.org/guideline/urological-infections
- http://www.szu.cz/pracovni-skupina-pro-monitorova-ni-rezistence-psmr